Overview

Patients who tear their ACL are at high risk for developing arthritis (post-traumatic osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to deterioration of joint health. This study will determine whether treatment with Tranexamic Acid (TXA), an FDA approved medication that reduces bleeding right after ACL injury and reconstructive surgery reduces inflammation and improves joint health as a new strategy to prevent or delay the onset of PTOA.

Eligibility

Inclusion Criteria:

• age 18-30 years
• within 4 days of unilateral ACL injury
• presence of effusion/hemarthrosis.

Exclusion Criteria:

• inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout/ pseudogout
• systemic or acute illness requiring medications
• concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery
• prior surgery to either knee
• prior injury to either knee requiring crutches
• history of thromboembolic disease
• current use of combination hormonal contraception
• chronic NSAID use
• cortisone injection to either knee within the prior 3 months
• not indicated for or unable to undergo ACLR within 3 months of injury